Luminopia Archives - Medical Design Sourcing

Luminopia raises $16M for digital lazy eye therapeutic

Luminopia announced that it raised $16 million to support its software-based therapeutic for amblyopia, commonly known as lazy eye.

Cambridge, Massachusetts-based Luminopia saw its oversubscribed Series A financing round led by U.S. Venture Partners (USVP). New investor Broadfin Advisors supported alongside existing investors ShangBay Capital and Vertical Group. In conjunction with the financing. USVP General Partner Casey Tansey joins Luminopia’s board.

Luminopia plans to use the funds to support the full commercial rollout of its lead product. This Lumiopia product, a software-based lazy eye therapeutic, received FDA de novo approval in October 2021. Its current availability comes through prescription use only through eye care professionals.

The system has an indication for improving visual acuity in children between ages 4-7 with amblyopia associated with anisometropia and/or with mild strabismus. It allows patients to watch therapeutically modi…

Luminopia’s new FDA-approved therapy uses TV to treat lazy eye in kids

Luminopia announced today that it received FDA de novo approval for its prescription therapy for improving vision in children with lazy eye.

Cambridge, Massachusetts-based Luminopia’s prescription Luminopia One holds indication for improvement in visual acuity in children between ages four and seven with lazy eye (amblyopia) associated with anisometropia and/or mild strabismus, having received treatment instructions as prescribed by a trained eye-care professional, according to a news release.

Get the full story at our sister site, Medical Design & Outsourcing.

Luminopia’s new FDA-approved therapy uses TV to treat lazy eye in kids

Luminopia announced today that it received FDA de novo approval for its prescription therapy for improving vision in children with lazy eye.

Cambridge, Massachusetts-based Luminopia’s prescription Luminopia One holds indication for improvement in visual acuity in children between ages four and seven with lazy eye (amblyopia) associated with anisometropia and/or mild strabismus, having received treatment instructions as prescribed by a trained eye-care professional, according to a news release.

“The FDA approval of a new digital therapy with robust clinical evidence for children affected by amblyopia is a major development. Amblyopia is one of the most common conditions I manage as a clinician, and patients, parents and physicians often struggle with current therapies,” Boston Children’s Hospital Ophthalmologist-in-Chief & Richard Robb Chair in Opthalmology & advisor to Luminopia Dr. David G. Hunte said in the release. “The idea of prescribin…